Literature DB >> 28826725

Dry powder aerosols to co-deliver antibiotics and nutrient dispersion compounds for enhanced bacterial biofilm eradication.

S Sommerfeld Ross1, S Gharse1, L Sanchez2, J Fiegel3.   

Abstract

The purpose of this study was to formulate a dry powder for inhalation containing a combination treatment for eradication of Pseudomonas aeruginosa bacterial biofilms. Dry powders containing an antibiotic (ciprofloxacin hydrochloride, CH) and nutrient dispersion compound (glutamic acid, GA) at a ratio determined to eliminate the biofilms were generated by spray drying. Leucine was added to the spray dried formulation to aid powder flowability. A central composite design of experiments was performed to determine the effects of solution and processing parameters on powder yield and aerodynamic properties. Combinations of CH and GA eradicated bacterial biofilms at lower antibiotic concentrations compared to CH alone. Spray dried powders were produced with yields up to 43% and mass mean aerodynamic diameters (MMAD) in the respirable range. Powder yield was primarily affected by variables that determine cyclone efficiency, i.e. atomizer and solution flow rates and solution concentration; while MMAD was mainly determined by solution concentration. Fine particle fractions (FPF)<4.46μm and <2.82μm of the powders ranged from 56 to 70% and 35 to 46%, respectively. This study demonstrates that dry powder aerosols containing high concentrations of a combination treatment effective against P. aeruginosa biofilms could be developed with high yield, aerodynamic properties appropriate for inhalation, and no loss of potency.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Central composite design; Ciprofloxacin; Fine particle fraction; Mass median aerodynamic diameter; Pseudomonas aeruginosa; Spray drying

Mesh:

Substances:

Year:  2017        PMID: 28826725      PMCID: PMC5597492          DOI: 10.1016/j.ijpharm.2017.08.060

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  44 in total

1.  Development of spray-dried acetaminophen microparticles using experimental designs.

Authors:  A Billon; B Bataille; G Cassanas; M Jacob
Journal:  Int J Pharm       Date:  2000-08-10       Impact factor: 5.875

Review 2.  In vitro/in vivo comparisons in pulmonary drug delivery.

Authors:  Stephen P Newman; Hak-Kim Chan
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2008-03       Impact factor: 2.849

Review 3.  Bacterial biofilms: development, dispersal, and therapeutic strategies in the dawn of the postantibiotic era.

Authors:  Maria Kostakioti; Maria Hadjifrangiskou; Scott J Hultgren
Journal:  Cold Spring Harb Perspect Med       Date:  2013-04-01       Impact factor: 6.915

Review 4.  Pulmonary drug delivery by powder aerosols.

Authors:  Michael Yifei Yang; John Gar Yan Chan; Hak-Kim Chan
Journal:  J Control Release       Date:  2014-05-09       Impact factor: 9.776

Review 5.  Antibiotic resistance in Pseudomonas aeruginosa biofilms: towards the development of novel anti-biofilm therapies.

Authors:  Patrick K Taylor; Amy T Y Yeung; Robert E W Hancock
Journal:  J Biotechnol       Date:  2014-09-18       Impact factor: 3.307

6.  Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of six years and older.

Authors:  H A Tiddens; D E Geller; P Challoner; R J Speirs; K C Kesser; S E Overbeek; D Humble; S B Shrewsbury; T A Standaert
Journal:  J Aerosol Med       Date:  2006

7.  Genome diversity of Pseudomonas aeruginosa PAO1 laboratory strains.

Authors:  Jens Klockgether; Antje Munder; Jens Neugebauer; Colin F Davenport; Frauke Stanke; Karen D Larbig; Stephan Heeb; Ulrike Schöck; Thomas M Pohl; Lutz Wiehlmann; Burkhard Tümmler
Journal:  J Bacteriol       Date:  2009-12-18       Impact factor: 3.490

8.  The Delivery of High-Dose Dry Powder Antibiotics by a Low-Cost Generic Inhaler.

Authors:  Thaigarajan Parumasivam; Sharon S Y Leung; Patricia Tang; Citterio Mauro; Warwick Britton; Hak-Kim Chan
Journal:  AAPS J       Date:  2016-09-27       Impact factor: 4.009

9.  Tobramycin administered by the TOBI(®) Podhaler(®) for persons with cystic fibrosis: a review.

Authors:  Donald R Vandevanter; David E Geller
Journal:  Med Devices (Auckl)       Date:  2011-09-20

Review 10.  Tobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic Fibrosis.

Authors:  John Lam; Steven Vaughan; Michael D Parkins
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2013-11-13
View more
  2 in total

1.  Design and Characterization of Spray-Dried Chitosan-Naltrexone Microspheres for Microneedle-Assisted Transdermal Delivery.

Authors:  Abayomi T Ogunjimi; Jennifer Fiegel; Nicole K Brogden
Journal:  Pharmaceutics       Date:  2020-05-29       Impact factor: 6.321

Review 2.  Current Status of In Vitro Models and Assays for Susceptibility Testing for Wound Biofilm Infections.

Authors:  Tania F Bahamondez-Canas; Lara A Heersema; Hugh D C Smyth
Journal:  Biomedicines       Date:  2019-04-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.